The company recently invested an additional €90m to expand its capabilities at its contact lens manufacturing plant in ...

Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares ...

A popular brand of eye drops is being recalled nationwide after a consumer reported a "foreign material" was found in a ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic competition in ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients ...

Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private ...

Bausch + Lomb Corp (NYSE:BLCO; TSX:BLCO), a global leader in eye health products, has recently experienced a mix of positive developments and challenges that have caught the attention of investors ...

Elios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...

Bausch + Lomb Corp (NYSE:BLCO; TSX:BLCO), a global leader in eye health products with a market capitalization of $6.86 billion, has recently experienced a mix of positive developments and challenges ...